Walleye Capital
ANIP icon

Walleye Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Walleye Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,200
Closed -$74K – 907
2019
Q4 		$74K Sell
1,200
-1,900
-61% -$126K ﹤0.01% 1428
2019
Q3 		$226K Buy
+3,100
New +$232K 0.01% 1143
2019
Q2 		– Sell
-2,000
Closed -$141K – 1712
2019
Q1 		$141K Buy
+2,000
New +$118K 0.02% 907

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's ANIP Position: Q2 2026 in Review

Walleye Capital reduced its ANI Pharmaceuticals (ANIP) stake by 42% in Q2 2026, selling an estimated $6.17M and leaving 106,112 shares worth $8.78M. The position accounts for 0.03% of the portfolio, ranked #536.

Walleye Capital first reported a position in ANIP in Q1 2019 and has held it in 14 quarters since. The position peaked at $19.8M in Q3 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Walleye Capital held 106,112 shares of ANI Pharmaceuticals worth $8.78M as of Q2 2026.
  • Walleye Capital sold 76,963 ANI Pharmaceuticals shares in Q2 2026, an estimated $6.17M.
  • ANI Pharmaceuticals made up 0.03% of Walleye Capital's portfolio in Q2 2026, its #536 holding.
  • Walleye Capital first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 14 quarters since.
  • Walleye Capital's ANI Pharmaceuticals position peaked at $19.8M in Q3 2025.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.